Pascal Soriot, AstraZeneca CEO (Yang Guanyu/Xinhua via Getty Images)
April 25, 2024 07:16 AM EDT
People
Pharma

As­traZeneca’s Pas­cal So­ri­ot says new rise in pay is ‘re­al­ly about’ po­ten­tial suc­ces­sor

Ayisha Sharma

News Reporter

As­traZeneca CEO Pas­cal So­ri­ot vig­or­ous­ly de­fend­ed his re­cent­ly se­cured $23.5 mil­lion pay pack­age, cit­ing the UK phar­ma’s need to com­pete for tal­ent.

“It re­al­ly is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times